GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nanobiotix NBTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

32.03

+4.57%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Nanobiotix

Its shares trade under the ticker NBTX. It has been listed since 11 December 2020. In the fiscal year to 31 December 2025, it reported revenue of $33.6m and a net loss of $27.2m. At that date it held total assets of $76.8m and shareholders' equity of −$95.8m.

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
11 Dec 2020
Employees
97
Head office
60 RUE DE WATTIGNIES, PARIS, I0, 75012
Incorporated in
I0
Classification
Pharmaceutical Preparations
Filer status
Accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • NBTXR3 targets multiple cancer types including soft tissue sarcoma and lung cancer.
  • The company has a partnership with Lian Oncology Limited for Asian markets.
  • Nanobiotix operates as a clinical-stage biotechnology firm focused on unmet medical needs.

Weaknesses

  • The company employs only 97 people, limiting its operational scale significantly.
  • NBTXR3 is still in the clinical stage and not yet commercially available.
  • The firm relies heavily on a single lead product candidate for growth.

Opportunities

  • Lian Oncology Limited can commercialize NBTXR3 in China, South Korea, Singapore, and Thailand.
  • Expanding into pancreatic and esophageal cancer treatments offers new market segments.
  • Developing products for other unmet medical needs diversifies the current portfolio.

Threats

  • Clinical trial failures for NBTXR3 could halt progress in treating soft tissue sarcoma.
  • Regulatory hurdles in China and South Korea may delay commercialization efforts.
  • Competitors in the biotechnology sector might develop superior nanoparticle treatments for cancer.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.